Rapport Therapeutics, Inc Common Stock
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -208 | -152 | ||
EBITDA | -21,421 | -20,800 | -16,942 | -13,338 |
EBIT | -21,640 | -21,008 | -17,094 | -13,391 |
Net Income | -17,537 | -18,121 | -22,669 | -13,519 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -16,555 | -17,319 | -18,687 | -11,794 |
Cash | 39,314 | 110,269 | 74,372 | 70,169 |
Basic Shares | 34,855 | 36,576 | 35,376 | 35,376 |
Annual Financials
| Values in thousands | 2023-12-31 |
|---|---|
Revenue | $0 |
Gross Profit | -112 |
EBITDA | -34,664 |
EBIT | -34,776 |
Net Income | -34,786 |
Net Change In Cash | 0 |
Free Cash Flow | -28,817 |
Cash | 70,169 |
Basic Shares | 164,352 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.47 |
2024-06-30 | -$1.70 |
